乳腺癌不同分子亚型的临床特点和生存分析

被引:109
作者
连臻强 [1 ,2 ]
何洁华 [1 ]
王曦 [1 ]
唐军 [1 ]
杨名添 [1 ]
机构
[1] 中山大学肿瘤防治中心乳腺科华南肿瘤学国家重点实验室
[2] 广东省妇幼保健院乳腺病中心
关键词
乳腺肿瘤; 分子亚型; HER-2; 预后;
D O I
暂无
中图分类号
R737.9 [乳腺肿瘤];
学科分类号
100214 [肿瘤学];
摘要
目的探讨乳腺癌各分子亚型的临床特点及其预后情况。方法回顾性分析482例可手术乳腺癌患者资料,以免疫组织化学技术为基础,把乳腺癌分为4种分子亚型:luminalA型[ER(+)或PR(+)且HER-2(-)],luminalB型[ER(+)或PR(+)且HER-2(+)],HER-2过表达型[ER(-)、PR(-)且HER-2(+)]和basal-like型[ER(-)、PR(-)且HER-2(-)],并分析其临床特点及预后情况。结果全组共482例,其中luminalA型占46.1%(222/482),luminalB型占14.7%(71/482),HER-2过表达型占10.4%(50/482),basal-like型占28.8%(139/482)。运用χ2检验各分子亚型在年龄、月经状况、肿瘤大小、淋巴结状况和临床分期等的差异均无统计学意义。全组有完整随访资料者共441例,中位随访时间62个月。随访结果显示,HER-2过表达型和basal-like型的远处转移率均高于luminalA型,且差异有统计学意义(χ2=11.659,P=0.009);运用Kaplan-Meier法分析各分子亚型的生存预后,luminalA型的无病生存率、无远处转移生存率和总生存率最高,HER-2过表达型和basal-like型的预后最差,差异有统计学意义(Log-Rank检验,P均<0.050)。结论乳腺癌分子分型对患者预后的判断具有重要临床意义,有望成为今后制定乳腺癌个体化治疗的重要依据。
引用
收藏
页码:139 / 146
页数:8
相关论文
共 4 条
[1]
Basal cell–like (triple-negative) breast cancer; a predictor of distant metastasis in African American women.[J].Chukwuemeka U. Ihemelandu;Tammey J. Naab;Haile M. Mezghebe;Kepher H. Makambi;Suryanarayana M. Siram;LaSalle D. Leffall;Robert L. DeWitty;Wayne A. Frederick.The American Journal of Surgery.2008, 2
[2]
Immunohistochemical and molecular subtypes of breast cancer in Nigeria [J].
Adebamowo, Clement A. ;
Famooto, Ayotunde ;
Ogundiran, Temidayo O. ;
Aniagwu, Toyin ;
Nkwodimmah, Chibuzor ;
Akang, Effiong E. .
BREAST CANCER RESEARCH AND TREATMENT, 2008, 110 (01) :183-188
[3]
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial [J].
Smith, Ian ;
Procter, Marion ;
D Gelber, Richard ;
Guillaume, Sebastien ;
Feyereislova, Andrea ;
Dowsett, Mitch ;
Goldhirsch, Aron ;
Untch, Michael ;
Mariani, Gabriella ;
Baselga, Jose ;
Kaufmann, Manfred ;
Cameron, David ;
Bell, Richard ;
Bergh, Jonas ;
Coleman, Robert ;
Wardley, Andrew ;
Harbeck, Nadia ;
Lopez, Roberto I. ;
Mallmann, Peter ;
Gelmon, Karen ;
Wilcken, Nicholas ;
Wist, Erik ;
Sanchez Rovira, Pedro ;
Piccart-Gebhart, Martine .
LANCET, 2007, 369 (9555) :29-36
[4]
Triple-negative breast cancer: clinical features and patterns of recurrence..Dent R;Trudeau M;Pritchard KI; et al;.Clin Cancer Res.2007, 15